SCOTUS Kicks Patent Eligibility Cases to the Curb in Last Move of the Term
… it up to Congress and the U.S. Patent and Trademark Office (USPTO) to restore any semblance of clarity on U.S. patent eligibility law for now.
PATENT NEWS
-
In: PATENT NEWS
-
In: PATENT NEWS
Change Could Be Coming to Patent Suit Volume in Texas – Troutman Pepper
Change Could Be Coming to Patent Suit Volume in Texas Troutman Pepper
-
In: PATENT NEWS
“Multi-Stable Compliant-Mechanism Mattress For Bed Sore Prevention” in Patent Application Approval Process (USPTO 20220175601): Patent Application – Insurance News Net
“Multi-Stable Compliant-Mechanism Mattress For Bed Sore Prevention” in Patent Application Approval Process (USPTO 20220175601): Patent Application Insurance News Net
-
In: PATENT NEWS
USPTO Report Underscores Split on State of US Patent Eligibility Jurisprudence – IPWatchdog.com
USPTO Report Underscores Split on State of US Patent Eligibility Jurisprudence IPWatchdog.com
-
In: PATENT NEWS
Paradigm Biopharmaceuticals lands IP Australia approval for bone marrow pathology treatment patent – Proactive Investors Australia
Paradigm Biopharmaceuticals lands IP Australia approval for bone marrow pathology treatment patent Proactive Investors Australia
-
In: PATENT NEWS
Nokia Whiffs on Bid to Get Patent Claims on DSL Tech Dismissed – Bloomberg Law
… LLC’s patent-infringement claims related to digital subscriber line, or DSL, … TQ Delta met federal law’s marking requirements, judge says …
-
In: PATENT NEWS
Kim Kardashian Hit With Trademark Lawsuit Over SKKN By Similarly-Named Co.
… as well as civil conspiracy under New York common law, for launching … the U.S. Patent and Trademark Office (“USPTO”)’s Trademark Trial and …
-
In: PATENT NEWS
Apple Patent Reveals Radical New iPhone Design Upgrades – Forbes
Apple Patent Reveals Radical New iPhone Design Upgrades Forbes
-
In: PATENT NEWS
Negative Claim Elements and the Importance of Complete Patent Disclosures: How Novartis …
On June 21, 2022, Novartis Pharmaceuticals Corp.’s patent for a method of treating multiple sclerosis with fingolimod (Gilenya®) was held invalid …
-
In: PATENT NEWS
Negative Claim Elements and the Importance of Complete Patent Disclosures: How Novartis Lost a $2.8 Billion Drug to Generic Drug Makers – Wilson Sonsini Goodrich & Rosati
Negative Claim Elements and the Importance of Complete Patent Disclosures: How Novartis Lost a $2.8 Billion Drug to Generic Drug Makers Wilson Sonsini Goodrich & Rosati